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Selective Amplification of Rare Mutations Using
Locked Nucleic Acid Oligonucleotides that
Competitively Inhibit Primer Binding to Wild-Type
DNA
Reid P. Oldenburg1, Monica S. Liu1 and Michael S. Kolodney1
Detection of mutated genomic DNA from cancer cells circulating in blood may improve tumor staging and
patient selection for targeted therapy. However, the task of detecting a few mutated cells in the presence of a
large excess of wild-type cells requires a sensitive and selective assay. We describe a novel approach to detect
circulating melanoma cells harboring a common point mutation in the BRAF kinase. In the first step, primer
binding to wild-type BRAF is competitively blocked by a locked nucleic acid (LNA) oligonucleotide. In the
second step, the LNA-blocking approach is combined with a mutant-specific forward primer. This two-step
approach easily detected 10 BRAF g[1799T4A]-mutated melanoma cells mixed with 105 wild-type cells. To
determine the clinical utility of this method, we tested its ability to detect human blood spiked with a defined
number of BRAF1799T4A-mutated melanoma cells. Blood was first enriched for melanoma cells using an
antibody-mediated negative selection procedure before whole genome amplification (WGA). Mutant BRAF in
the WGA-amplified genomic DNA was further amplified by a two-step real-time PCR protocol. Using this
approach, we could readily identify mutant DNA from as few as 10 melanoma cells in 1ml of human blood.
Journal of Investigative Dermatology (2008) 128, 398–402; doi:10.1038/sj.jid.5700920; published online 21 June 2007
INTRODUCTION
A substantial fraction of melanomas contain a point or
tandem oncogenic mutation in exon 15 of BRAF, a
cytoplasmic serine/threonine kinase in the MAPK pathway
(Kumar et al., 2003). These mutations cause constitutive
activation of B-raf kinase resulting in downstream activation
of the MEK/ERK pathway (Davies et al., 2002). Because of the
high prevalence of oncogenic BRAF mutations in certain
cancers, methods are being developed to detect these
mutations in clinical specimens. Since most clinical speci-
mens contain a mixture of cell types, these approaches must
be able to detect mutations in tissue samples that often
contain an excess of wild-type DNA mixed with mutant DNA.
Allele-specific PCR (AS-PCR) can detect at least one
mutant copy of genomic DNA in 102 wild-type copies (Jarry
et al., 2004). This method utilizes a forward primer with a 30
terminal or penultimate nucleotide that matches to the
mutant rather than the wild-type sequence. The selectivity
of this technique is limited by inadvertent amplification of
wild-type DNA, producing a false mutant template that is
propagated by future PCR cycles. PCR restriction fragment
length polymorphism mapping (PCR-RFLP) involves PCR
amplification followed by digestion with an enzyme that
selectively cuts mutant DNA (Cohen et al., 2003). This
approach is somewhat qualitative and cannot be used for low
ratios of mutant/wild-type sequences. Clamping or wild-type-
blocking PCR (WTB-PCR) approaches utilize the discrimina-
tory properties and nuclease resistance of locked nucleic acid
(LNA) or peptide nucleic acid-substituted oligonucleotides.
These oligonucleotides selectively bind to the wild-type DNA
sequence to inhibit elongation of the amplicon on wild-type
template but not on mutant template (Dominguez and
Kolodney, 2005). However, elongation of the forward primer
upstream of the mutation creates a partially extended
product, which is more likely to amplify wild-type DNA
owing to its increased annealing temperature. To further
increase the specificity of WTB-PCR, primer-blocking PCR
(PB-PCR) was developed to avoid the generation of an
extended forward primer. PB-PCR improves on the specificity
of WTB-PCR by moving the forward primer downstream,
allowing the blocker to directly inhibit the binding of the
primer (Saadat et al., unpublished data).
Since the techniques described above can detect a few
mutant cells in heterogeneous tissue, they may be applicable
to clinical specimens containing as few as 1–10 melanoma
cells circulating per ml of peripheral blood (Koyanagi et al.,
2005). Sensitive detection of these circulating melanoma
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cells may predict tumor progression (Pantel and Doeberitz,
2000). However, these BRAF PCR-based techniques are not
selective enough to detect the approximate 106-fold ratio of
melanoma cells to nucleated blood cells present in clinical
samples from melanoma patients (Koyanagi et al., 2005).
Current clinical approaches to detecting circulating
melanoma cells rely on reverse transcription-PCR (RT-PCR).
RT-PCR detects expression of melanocyte-specific transcripts
such as tyrosinase. Under ideal circumstances, RT-PCR can
sensitively detect as few as one melanoma cell per 10ml of
blood (Keilholz et al., 1998). However, because RT-PCR
relies on mRNA expression, illegitimate transcription and the
inherent instability of mRNA limit its clinical applicability
(Keilholz et al., 1998). To avoid the inconsistency of RT-PCR
assays, we developed primer-blocking allele-specific PCR
(PBAS-PCR), a selective assay that directly targets BRAF-
mutated genomic DNA in melanoma cells that circulate in
blood. PBAS-PCR employs the additive effect of using an AS
forward primer and a competitive LNA blocker to maximize
inhibition of wild-type amplification without adversely
affecting the detection of mutant sequences. In this report,
we describe our studies using PBAS-PCR to quantitatively
assay defined cell mixtures and whole blood for the presence
of mutated BRAF.
RESULTS
Combining AS forward primer and LNA blocking to increase
specificity
Both AS primers and LNA blocking approaches have
previously been shown to increase the selectivity of PCR-
based mutation detection methods (Jarry et al., 2004; Saadat
et al., unpublished data). We combined LNA blocking with
AS primers in PBAS-PCR to maximize selectivity. The
mechanism of PBAS-PCR is illustrated in Figure 1a. The AS
forward primer selectively amplifies mutant BRAF DNA,
while the LNA blocker directly inhibits the binding of the AS
forward primer to the wild-type sequence without inhibiting
amplification by binding to the mutant BRAF sequence.
To demonstrate the additive effect of the AS forward
primer and LNA blocker in the detection of mutated BRAF,
we amplified genomic DNA isolated from wild-type (HEK
293T) and BRAF-mutated (A375M) cell lines. The substitution
of an AS forward primer for a non-AS primer delayed wild-
type amplification by 18 cycles (Figure 1b). In contrast,
primer substitution caused a five-cycle decrease for mutant
template (Figure 1c). The addition of LNA blocker to the AS
primer further increased the delay in wild-type amplification
to 25 cycles (Figure 1b). In contrast to its effect on wild-type
template, the addition of an LNA blocker did not inhibit
mutant amplification, demonstrating that the LNA blocker
only targets wild-type BRAF (Figure 1c). In summary, using
both an AS forward primer and an LNA blocker in the same
PCR reaction improves sensitivity of detection of mutated
BRAF while inhibiting the amplification of wild-type
sequences.
Detection of BRAF mutations in genomic DNA using two-step
PBAS-PCR
To allow more amplification cycles without falsely amplify-
ing wild-type template, we developed a two-step PCR
protocol. Two-step PBAS-PCR exploits the additive effects
of the AS forward primer and the LNA blocker. During both
steps, LNA blocker selectively inhibited wild-type amplifica-
tion. In the first step (not shown), a non-AS forward primer
was used, so that amplification errors would not generate an
amplicon containing the 1799T4A BRAF mutation that
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Figure 1. LNA blocking oligonucleotide increases the specificity without decreasing sensitivity. (a) Combining an AS forward primer with LNA blocking in
PBAS-PCR. The AS forward primer selectively amplifies the mutant BRAF while the LNA blocker inhibits the binding of the AS forward primer to the wild-type
sequence. (b) Amplification of BRAF exon 15 from 105 copies of wild-type genomic DNA. (i) Non-AS primers without LNA blocker; (ii) AS primers without LNA
blocker; and (iii) AS primers with LNA blocker. (c) Amplification of BRAF exon 15 from 10 copies of BRAF-mutated genomic DNA. Bars¼ (b) 2 cm, (c) 2 cm.
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would be propagated in subsequent cycles. In the second
step, we used the 1:500 diluted amplicon from the first step
with the AS forward primer to increase selectivity for mutant
BRAF by only amplifying BRAF-mutated DNA. As shown in
Figure 2, 10 copies of mutant BRAF genomic DNA amplified
at cycle 40, while amplification of 105 copies of wild-type
BRAF was undetectable even after 60 cycles. Since this assay
creates a 20-cycle gap between the amplification of mutant
and wild-type genomic samples, two-step PBAS-PCR is ideal
for detecting a low copy number of mutated BRAF sequences
in the presence of an excess of wild-type DNA.
Detection of BRAF-mutated melanoma cells in blood
To determine if two-step PBAS-PCR could detect rare BRAF-
mutated melanoma cells in peripheral blood, we spiked
human whole blood with a defined number of A375M cells
(range: 101–104 cells/ml blood). We then used a negative
epithelial cell enrichment procedure to remove approxi-
mately 85% of leukocytes from blood by crosslinking CD45-
antibody-labeled hematopoietic cells to red blood cells
(Lansdorp and Thomas, 1990). Whole genome amplification
(WGA) was then performed on DNA from the enriched cells
to increase the DNA copy number by approximately 4,000-
fold, thereby facilitating earlier amplification of all samples
(Hosono et al., 2003). Figure 3 shows the results of a two-step
PBAS-PCR procedure following epithelial cell enrichment
and WGA. PBAS-PCR detected 10 melanoma cells after 20
cycles of amplification, while 73 cycles were necessary to
amplify the epithelial-enriched fraction of unspiked blood.
Amplification of mutant samples was also dose-dependent,
indicating the reliability and accuracy of selective amplifica-
tion by two-step PBAS-PCR.
DISCUSSION
Detecting circulating melanoma cells in peripheral blood
may prove useful in tracking tumor progression and predict-
ing clinical outcomes (Ulmer et al., 2004). Our study
demonstrates that a novel AS-PCR approach combined with
epithelial cell enrichment and WGA can detect circulating
mutated cells in peripheral blood by amplifying rare BRAF-
mutated genomic DNA sequences. Our assay can reprodu-
cibly detect as few as 10 BRAF-mutated melanoma cells in
1ml of blood. By using an antibody-mediated negative
selection cell enrichment procedure in conjunction with
WGA, we can remove the majority of non-melanoma cells
while retaining melanoma cells for PCR detection.
Dividing the PCR procedure into two steps maximized the
selectivity of PBAS-PCR. The first step, in which non-allele-
specific primers and LNA blocker were used, inhibits
amplification of wild-type DNA. Since the non-allele-specific
forward primer does not contain the mutation site, priming
errors were not propagated through synthesis of mutant
template in the early half of the amplification process. During
the second step, the additive effects of the AS primer and the
LNA blocker allow more selective amplification of mutant
BRAF and further inhibition of wild-type amplification. PBAS-
PCR selectively amplifies the mutant BRAF sequence in a
dose-dependent manner, allowing for relative quantification
of the number of mutant cells present. Moreover, PBAS-PCR
did not amplify wild-type samples until a much later cycle,
thus facilitating clear identification of the BRAF mutation.
Detection of cancer cells in blood by amplifying cancer-
specific mutations may serve as an alternative to RT-PCR-
based techniques that detect circulating cancer cells, by cell
type-specific mRNAs. Recent studies suggest that RT-PCR can
identify as few as one melanoma cell per 10ml of blood by
detecting tyrosinase expression (Koyanagi et al., 2005).
However, the inherent instability of mRNA decreases the
reproducibility of this approach, and the resulting variability
among different laboratories limits its clinical use. By using
genomic DNA, we avoid problems involving mRNA in-
stability and false transcription of mRNA.
Since the viability of DNA taken from circulating tumor
cells may differ from DNA taken from purified melanoma cell
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Figure 2. Selective amplification of 101 copies of mutant BRAF using PBAS-
PCR. Genomic DNA from BRAF mutant (A375) or wild-type (HEK 293) cells
amplified by two-step PBAS-PCR. In the first step (not shown), non-AS primers
were combined with the LNA blocker for 30 cycles of amplification. An
aliquot of the first reaction was then used as template for a second PCR
reaction with both AS primers and LNA blocker. Bar¼ 2 cm.
3.0
2.0
1.0
0
102 mel
103 mel
104 mel 101 mel
0 mel
Cycle
Delta Rn
5 15 25 35 45 55 65 75
Figure 3. Detection of melanoma cells in whole human blood using PBAS-
PCR. One milliliter of whole human blood was spiked with a defined number
(0–104 cells) of BRAF-mutated melanoma cells (mel). After epithelial cell
enrichment by antibody-mediated negative selection, WGA was performed
before PBAS-PCR to facilitate earlier amplification of all samples. Samples
were amplified using two-step PBAS-PCR (first step not shown). The first step
amplified BRAF exon 15 using non-AS primers and an LNA blocker for 30
cycles. The second step used both AS-primers and an LNA blocker for 99
cycles. Bar¼ 2 cm.
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lines expanded ex vivo, further investigation is needed to
determine sensitivity of PBAS-PCR in clinical samples. Future
clinical studies will test the affectivity of PBAS-PCR in blood
taken from patients known to have BRAF-mutated tumors
with varying levels of disease progression or metastasis. By
quantifying and identifying genomic BRAF-mutated DNA,
PBAS-PCR could potentially assist in early diagnosis and in
staging of melanoma. Moreover, detection of BRAF-mutated
melanoma cells in blood using PBAS-PCR could identify
candidate patients who would benefit from agents targeting
the constitutively activated MAPK signaling pathway since
cells harboring oncogenic BRAF mutations are uniquely
susceptible to these agents (Collison et al., 2003; Solit et al.,
2006).
MATERIALS AND METHODS
Cell lines, tissue sources, and genomic DNA preparation
The Human Studies Committee of the LA Biomedical Research
Institute approved all described studies, and the study was
conducted according to the Declaration of Helsinki Principles.
HEK 293T cells, which do not contain oncogenic BRAF mutations,
were purchased from Invitrogen Incorporated (Carlsbad, CA).
A375M cells (ATCC catalog no. CRL-1619), which are homozygous
for the V599E BRAF mutation, were obtained as a gift from Dr R.O.
Hynes, MIT (Cambridge, MA). Whole human blood was drawn from
healthy volunteers with informed consent. Fresh blood was used for
each experiment.
DNA and LNA oligonucleotides
Sequence-specific oligonucleotides were designed and purchased
from Integrated DNA Technologies (Coralville, IA):
non-allele-specific forward primer: 50-AGGTGATTTTGGTCT
AGCTACAG-30; Allele-specific forward primer: 50-AGGTGATTTT
GGTCTAGCTACAGA-30; Reverse primer: 50-TAGTAACTCAGCAG
CATCTCAGGGC-30; LNA blocker (previously described by Dom-
inguez and Kolodney, 2005): 50-GCT ACA GTG AGG G-30; bold
signifies LNA nucleotide.
DNA enrichment and purification from blood
A375M cells were counted and suspended to 105 cells/ml 1 PBS
by standard counting procedure. To obtain a concentration of
10 cells/ml blood, the cell suspension was serially diluted and added
to the blood.
The RosetteSeps CD45 Depletion Cocktail for Epithelial Tumor
Cell Enrichment (product no. 15122/15162) from StemCell Tech-
nologies Inc. (Vancouver, BC, Canada) was used to isolate
suspended tumor cells from whole blood. The RosetteSep crosslinks
hematopoietic cells in whole blood to red blood cells, forming
immunorosettes. When centrifuged over Ficoll-PaqueTM PLUS
(catalog no. 07907, from Stem Cell Technologies Inc.), a buoyant
density medium, the non-tumor cells and the free red blood cells
pellet. Since tumor cells were not labeled with antibody, they settle
at the plasma: Ficoll-Paque PLUS interface. Modifications of the
recommended procedure include the following: substitution of
DMEMþ 2% FBS for PBSþ 2% FBS, and dilution of enriched cells
with 8ml 1 PBSþ 2% FBS.
Cells were pelleted out of PBS washing solution by centrifuging
for 10minutes at 2,500 r.p.m. PBS washing solution was aspirated
until 200ml remained, then resuspended and transferred to a new
microcentrifuge tube. Samples were centrifuged at 10,000 r.p.m. to
remove PBS without disturbing the pellet. The sample then under-
went WGA.
Primer-blocking allele-specific PCR
Before PCR, WGA was performed using the REPLI-g Mini Kits
(Qiagen Inc., Valencia, CA) to uniformly amplify genomic DNA with
minimal sequence bias (Hosono et al., 2003). Following WGA, the
samples were diluted 1:10 in TE for real-time PCR reactions. In
preparation for a 25 ml real-time PCR reaction, a master mix was
made with the following components: 12.5 ml QuantiTect SYBRs
Green Master Mix (Qiagen Inc.); in substitution for the Titanium Taq
PCR buffers, 1/1,000 dilution of SYBR Green I probe, and mutated
Taq polymerase (Stoffel fragments) used in previous assays),
7.5 pmol (0.75ml) forward and reverse primer, 9ml of nuclease-free
H2O, and 1 nmol (1ml) of LNA blocker. To this master mix, 1 ml of
template DNA was added. Mutant and wild-type samples were
loaded into 96-well reaction plates and amplified in the ABI Prisms
7000 Sequence Detection System (Applied Biosystems Inc., Foster
City, CA) in a two-step procedure (PBAS-PCR). During the first step,
samples were amplified for 30 cycles using non-allele-specific
forward primers and LNA blocker. For the second step, the amplicon
was diluted 1:500 in water and was re-amplified in a 99-cycle
reaction using an allele-specific forward primer and an LNA blocker.
Amplification parameters were as follows: Taq polymerase activa-
tion, 951 for 15minutes; denaturation, 951 for 15 seconds; annealing,
661 for 30 seconds; and extension, 721 for 30 seconds. Post-
amplification procedures included analysis of amplification plots
and dissociation curves.
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